Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine
- First Online:
- 192 Downloads
Clofarabine increases the activation of 1-β-d-arabinofuranosyl cytosine (araC) in tumor cells, and combination of these two drugs has been shown to result in good clinical activity against various hematologic malignancies. 1-β-d-[4-thio-arabinofuranosyl] cytosine (T-araC) is a new cytosine analog that has exhibited excellent activity against a broad spectrum of human solid tumors and leukemia/lymphoma xenografts in mice and is currently being evaluated in patients as a new drug for the treatment of cancer. Since T-araC has a vastly superior preclinical efficacy profile in comparison to araC, we have initiated studies to determine the potential value of clofarabine/T-araC combination therapy.
In vitro studies have been conducted to determine the effect of clofarabine on the metabolism of T-araC, and in vivo studies have been conducted to determine the effect of the clofarabine/T-araC combination on five human tumor xenografts in mice.
Initial studies with various tumor cells in culture indicated that a 2-h incubation with clofarabine enhanced the metabolism of T-araC 24 h after its removal by threefold in three tumor cell types (HCT-116 colon, K562 leukemia, and RL lymphoma) and by 1.5-fold in two other tumor cell types (MDA-MB-435 breast (melanoma), and HL-60 leukemia). Pretreatment with clofarabine resulted in a slight decrease in metabolism of T-araC in RPMI-8226 myeloma cells (65% of control) and inhibited metabolism of T-araC in CCRF-CEM leukemia cells by 90%. In vivo combination studies were conducted with various human tumor xenografts to determine whether or not the modulations observed in vitro were reflective of the in vivo situation. Clofarabine and T-araC were administered on alternate days for five treatments each (q2dx5) with the administration of T-araC 24 h after each clofarabine treatment. Combination treatment of HCT-116, K562, HL-60, or RL tumors with clofarabine and T-araC resulted in dramatically superior anti-tumor activity than treatment with either agent alone, whereas this combination resulted in antagonism in CCRF-CEM tumors. The in vivo antitumor activity of clofarabine plus T-araC against HCT-116 tumors was much better than the activity seen with clofarabine plus araC.
These studies provide a rationale for clinical trials using this combination in the treatment of acute leukemias as well as solid tumors and suggest that this combination would exhibit greater antitumor activity than that of clofarabine plus araC.
KeywordsClofarabine Arabinofuranosyl cytosine 1-β-d-[4-Thio-arabinofuranosyl]-cytosine Anti-solid tumor activity Synergistic antitumor activity
- 5.Faderl S, Gandhi V, O’Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H (2005) Results of a phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:940–947PubMedCrossRefGoogle Scholar
- 6.Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O’Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM (2006) Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108:45–51PubMedCrossRefGoogle Scholar
- 8.Tiwari KN, Shortnacy-Fowler AT, Cappellacci L, Parker WB, Waud WR, Montgomery JA, Secrist JA III (2000) Synthesis of 4′-thio-β-d-arabinofuranosyl-cytosine (4′-thio-ara-C) and comparison of its anticancer activity with that of ara-C. Nucleosides Nucleotides Nucleic Acids 19:329–340PubMedCrossRefGoogle Scholar
- 10.Waud WR, Shepherd RV, Gilbert KS, Tiwari KN, Secrist JA III (2004) Precinical antitumor activity of 4′-thio-β-d-arabinofuranosylcytosine (4′-thio-ara-C, OSI-7836) in human leukemia and lymphoma xenograft models. Proc Am Assoc Cancer Res 45:714Google Scholar
- 12.Richardson F, Black C, Richardson K, Franks A, Wells E, Karimi S, Sennello G, Hart K, Meyer D, Emerson D, Brown E, LeRay J, Nilsson C, Tomkinson B, Bendele R (2005) Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors. Cancer Chemother Pharmacol 55:213–221PubMedCrossRefGoogle Scholar
- 14.Richardson KA, Vega TP, Richardson FC, Moore CL, Rohloff JC, Tomkinson B, Bendele RA, Kuchta RD (2004) Polymerization of the triphosphates of AraC, 2′,2′-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase. Biochem Pharmacol 68:2337–2346PubMedCrossRefGoogle Scholar
- 18.Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK, Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group (2006) A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Cancer Chemother Pharmacol 58:703–710PubMedCrossRefGoogle Scholar
- 19.Lee CP, de Jonge MJ, O’Donnell AE, Schothorst KL, Hanwell J, Chick JB, Brooimans RA, Adams LM, Drolet DW, de Bono JS, Kaye SB, Judson IR, Verweij J (2006) A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. Clin Cancer Res 12:2841–2848PubMedCrossRefGoogle Scholar
- 20.Dykes DJ, Abbott BJ, Mayo JG, Harrison SD Jr, Laster WR, Simpson-Herren L, Griswold DP Jr (1992) Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol Basel Karger 42:1–22Google Scholar
- 23.Parker WB, Shaddix SC, Chang CH, White EL, Rose LM, Brockman RW, Shortnancy AT, Montgomery JA, Secrist JA III, Bennett LL Jr (1991) Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5-triphosphate. Cancer Res 51:2386–2394PubMedGoogle Scholar
- 25.Parker WB, Shaddix SC, Rose LM, Shewach DS, Hertel LW, Secrist JA III, Montgomery JA, Bennett LL Jr (1999) Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-d-ribofuranosyl) adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-β-d-ribofuranosyl) adenine in CEM cells. Mol Pharmacol 55:515–520PubMedGoogle Scholar